iressa in perspective don stribling 1 a astrazeneca annual business review october 2003 vp key brand team aastrazeneca registration status bapproved japan us and other markets argentina australia korea malaysia mexico singapore taiwan philippines future fda commitments agreed 1st study started beuropean application filed feb via central route brow applications submitted under 2 launch 19th may 03 strong take off b orders placed date of approval drug packed shipped within 7 days smooth transition patients from compassionate use programme dedicated support provided for obtaining insurance coverage where possible patient assistance available companies almost universally covering all state medicaids currently reimburse on dept defence mail order formulary over 10 000 treatment 0 5 3 augustjulyjunemay source ims health ddd weekly m per week audited sales
